Concepedia

The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent

Emile R. Mohler, Christie M. Ballantyne, Michael H. Davidson, M Hanefeld, Luís M. Ruilope, Joel L. Johnson, Andrew Zalewski

Journal of the American College of Cardiology · 2008 · 209 citations · 39 references

DOI

Concepts

References

39

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

Christopher P. Cannon, Eugene Braunwald, Carolyn H. McCabe et al. · New England Journal of Medicine · 2004 · 4.9K citations · Full text

, , +17

C-Reactive Protein Levels and Outcomes after Statin Therapy

Paul M. Ridker, Christopher P. Cannon, David A. Morrow et al. · New England Journal of Medicine · 2005 · 2.3K citations · Full text

, , +14

Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease

Steven E. Nissen, E. Murat Tuzcu, Paul Schoenhagen et al. · New England Journal of Medicine · 2005 · 1.3K citations

, , +17

Lipoprotein-Associated Phospholipase A<sub>2</sub>as an Independent Predictor of Coronary Heart Disease

Chris J. Packard, D S O’Reilly, Muriel Caslake et al. · New England Journal of Medicine · 2000 · 813 citations · Full text

, , +15

Lipoprotein-Associated Phospholipase A <sub>2</sub> , High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study

Christie M. Ballantyne, Ron C. Hoogeveen, Heejung Bang et al. · Circulation · 2004 · 617 citations · Full text

, , +16